milrinone has been researched along with 9-(2-hydroxy-3-nonyl)adenine in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (83.33) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, G; Ke, H; Kunz, S; Martinelli, S; Robinson, H; Seebeck, T; Wan, Y; Wang, H | 1 |
| Brenna, KJ; Colman, RW; Manns, JM; Sheth, SB | 1 |
| Hernández, J; Juan-Fita, MJ; Vargas, ML | 1 |
| Lazar, MJ; Punjabi, K; Scholz, PM; Tse, J; Weiss, HR | 1 |
| Cho, KW; Cui, X; Jin, JY; Kim, SH; Kim, SM; Kim, SZ; Lee, HS; Wen, JF | 1 |
| Kaneda, T; Nakajyo, S; Shimizu, K; Urakawa, N | 1 |
| Kaneda, T; Nakajyo, S; Shimizu, K; Urakawa, N; Watanabe, A | 1 |
| Davidov, T; Lazar, M; Molino, B; Rodriguez, R; Scholz, PM; Su, J; Tse, J; Weiss, HR; Zhang, Q | 1 |
| Abbott, BM; Thompson, PE | 1 |
| Hughes, RA; Manallack, DT; Thompson, PE | 1 |
| Axe, FU; Bembenek, SD; Butler, CR; Coles, F; Dunford, PJ; Edwards, JP; Fourie, AM; Grice, CA; Karlsson, L; Lundeen, K; Riley, JP; Savall, BM; Tays, KL; Wei, J; Williams, KN; Xue, X | 1 |
| Bucki, A; Chłoń-Rzepa, G; Funk, P; Gawalska, A; Lemrová, B; Nowak, B; Pawłowski, M; Pociecha, K; Ručilová, V; Soural, M; Świerczek, A; Vanda, D; Wyska, E; Zadrożna, M; Zajdel, P | 1 |
1 review(s) available for milrinone and 9-(2-hydroxy-3-nonyl)adenine
| Article | Year |
|---|---|
The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases.
Topics: Animals; Binding Sites; Crystallography, X-Ray; Cyclic AMP; Cyclic GMP; Drug Design; Humans; Models, Molecular; Molecular Structure; Phosphodiesterase Inhibitors; Quantitative Structure-Activity Relationship; Xanthines | 2005 |
11 other study(ies) available for milrinone and 9-(2-hydroxy-3-nonyl)adenine
| Article | Year |
|---|---|
Biological and structural characterization of Trypanosoma cruzi phosphodiesterase C and Implications for design of parasite selective inhibitors.
Topics: Amino Acid Sequence; Bridged Bicyclo Compounds, Heterocyclic; Catalytic Domain; Conserved Sequence; Crystallography, X-Ray; Drug Design; Kinetics; Molecular Sequence Data; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Protein Binding; Protein Structure, Secondary; Protozoan Proteins; Recombinant Proteins; Saccharomyces cerevisiae; Sulfonamides; Surface Properties; Trypanosoma cruzi | 2012 |
Differential regulation of human platelet responses by cGMP inhibited and stimulated cAMP phosphodiesterases.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adenine; Adult; Blood Platelets; Calcium; Calcium Signaling; Cell Adhesion Molecules; Cyclic AMP; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 2; Cyclic Nucleotide Phosphodiesterases, Type 3; Enzyme Inhibitors; Humans; Microfilament Proteins; Milrinone; Phosphoproteins; Phosphoric Diester Hydrolases; Phosphorylation; Platelet Aggregation; Platelet Aggregation Inhibitors; Protein Processing, Post-Translational; Second Messenger Systems | 2002 |
Comparative actions of diazepam and other phosphodiesterase inhibitors on the effects of noradrenaline in rat myocardium.
Topics: Adenine; Animals; Cyclic AMP; Diazepam; Dose-Response Relationship, Drug; Drug Synergism; Female; In Vitro Techniques; Isoenzymes; Male; Milrinone; Myocardial Contraction; Norepinephrine; Phosphodiesterase Inhibitors; Rats; Rats, Sprague-Dawley; Rolipram; Xanthines | 2003 |
Negative functional effects of cyclic GMP are altered by cyclic AMP phosphodiesterases in rabbit cardiac myocytes.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adenine; Animals; Cell Size; Cyclic AMP; Cyclic GMP; Dose-Response Relationship, Drug; Milrinone; Myocytes, Cardiac; Phosphodiesterase Inhibitors; Rabbits; Thionucleotides | 2003 |
High and low gain switches for regulation of cAMP efflux concentration: distinct roles for particulate GC- and soluble GC-cGMP-PDE3 signaling in rabbit atria.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adenine; Animals; Atrial Natriuretic Factor; Biological Transport; Cardiac Pacing, Artificial; Cyclic AMP; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 2; Cyclic Nucleotide Phosphodiesterases, Type 3; Enzyme Inhibitors; Guanylate Cyclase; Heart Atria; Milrinone; Molsidomine; Myocardial Contraction; Myocytes, Cardiac; Natriuretic Peptide, C-Type; Nitric Oxide Donors; Oxadiazoles; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Pyrazoles; Pyridines; Quinoxalines; Rabbits; Receptors, Cytoplasmic and Nuclear; Second Messenger Systems; Soluble Guanylyl Cyclase; Stroke Volume | 2004 |
Effects of various selective phosphodiesterase inhibitors on carbachol-induced contraction and cyclic nucleotide contents in guinea pig taenia coli.
Topics: Adenine; Animals; Carbachol; Colforsin; Colon; Cyclic AMP; Cyclic GMP; Dose-Response Relationship, Drug; Guinea Pigs; Male; Milrinone; Muscle Contraction; Nitroprusside; Nucleotides, Cyclic; Phosphodiesterase Inhibitors; Purinones; Vinca Alkaloids | 2004 |
Effects of various selective phosphodiesterase inhibitors on carbachol-induced contraction and cyclic nucleotide contents in the guinea pig gall bladder.
Topics: 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; Adenine; Animals; Carbachol; Cyclic AMP; Cyclic GMP; Gallbladder; Guinea Pigs; Male; Milrinone; Muscle Contraction; Nucleotides, Cyclic; Phosphodiesterase Inhibitors; Purinones; Vinca Alkaloids | 2005 |
Reduction in interaction between cGMP and cAMP in dog ventricular myocytes with hypertrophic failure.
Topics: Adenine; Animals; Body Weight; Cardiotonic Agents; Cyclic AMP; Cyclic GMP; Dogs; Drug Interactions; Enzyme Inhibitors; Heart Failure; Hypertrophy, Left Ventricular; Milrinone; Myocardial Contraction; Myocytes, Cardiac; Organ Size; Signal Transduction | 2005 |
PDE2 inhibition by the PI3 kinase inhibitor LY294002 and analogues.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Blood Platelets; Chromones; Cyclic Nucleotide Phosphodiesterases, Type 2; Cyclic Nucleotide Phosphodiesterases, Type 3; Dose-Response Relationship, Drug; Humans; Morpholines; Phosphodiesterase Inhibitors; Phosphoinositide-3 Kinase Inhibitors; Phosphoric Diester Hydrolases; Structure-Activity Relationship | 2004 |
Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Catalysis; Dogs; Drug Evaluation, Preclinical; Enzyme Inhibitors; Epoxide Hydrolases; Humans; Magnetic Resonance Spectroscopy; Mice; Structure-Activity Relationship | 2008 |
New imidazopyridines with phosphodiesterase 4 and 7 inhibitory activity and their efficacy in animal models of inflammatory and autoimmune diseases.
Topics: Animals; Anti-Inflammatory Agents; Autoimmune Diseases; Cyclic Nucleotide Phosphodiesterases, Type 7; Disease Models, Animal; Female; Humans; Imidazoles; Inflammation; Male; Mice, Inbred BALB C; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pyridines; Rats, Wistar | 2021 |